Raf-1 and B-Raf promote protein kinase C θ interaction with BAD

被引:15
|
作者
Hindley, Alison
Kolch, Walter
机构
[1] Beatson Inst Canc Res, Signalling & Proteom Lab, Glasgow G1 1BD, Lanark, Scotland
[2] Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland
关键词
T-cells; Raf-1; B-Raf; PKC theta; BAD; phosphorylation; signal transduction;
D O I
10.1016/j.cellsig.2006.08.004
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
PKC theta regulates the proliferation, survival and differentiation of T-cells. Here we show that PKC theta interacts with Raf-1 and B-Raf kinases. Raf-1 enhanced the kinase activity of associated PKC theta, while PKC theta reduced the catalytic activity of associated Raf-1. In contrast, B-Raf binding did not affect PKC theta kinase activity, and PKC theta did not change B-Raf activity. Coexpression of mutationally activated Raf-1 in cells enhanced the phosphorylation of T538 in the PKC theta activation loop. PKC theta and Raf cooperated in terms of binding to BAD, a pro-apoptotic Bcl-2 family protein that is inactivated by phosphorylation. While neither Raf-1 nor B-Raf could phosphorylate BAD, they enhanced the ability of PKC theta to interact with BAD and to phosphorylate BAD in vitro and in vivo, suggesting a new role for Raf proteins in T-cells by targeting PKC theta to interact with and phosphorylate BAD. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:547 / 555
页数:9
相关论文
共 50 条
  • [41] Untying the regulation of the Raf-1 kinase
    Dhillon, AS
    Kolch, W
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2002, 404 (01) : 3 - 9
  • [42] Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis
    Kern, F.
    Doma, E.
    Rupp, C.
    Niault, T.
    Baccarini, M.
    ONCOGENE, 2013, 32 (19) : 2483 - 2492
  • [43] The synthesis of a novel inhibitor of B-Raf kinase
    Denni-Dischert, D
    Marterer, W
    Bänziger, M
    Yusuff, N
    Batt, D
    Ramsey, T
    Geng, P
    Michael, W
    Wang, RMB
    Taplin, F
    Versace, R
    Cesarz, D
    Perez, LB
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2006, 10 (01) : 70 - 77
  • [44] VEMURAFENIB B-raf Kinase Inhibitor Oncolytic
    Puzanov, I.
    Flaherty, K. T.
    Sosman, J. A.
    Grippo, J. F.
    Su, F.
    Nolop, K.
    Lee, R. J.
    Bollag, G.
    DRUGS OF THE FUTURE, 2011, 36 (03) : 191 - 199
  • [45] B-Raf kinase inhibitors for cancer treatment
    Li, Nanxin
    Batt, David
    Warmuth, Markus
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (06) : 452 - 456
  • [46] Development of potent inhibitors of B-Raf kinase
    Wei, Jianmei
    Wolin, Ronald
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [47] INTERACTION OF THE PROTEIN-KINASE RAF-1 WITH 14-3-3-PROTEINS
    FU, H
    XIA, K
    PALLAS, DC
    CUI, C
    CONROY, K
    NARSIMHAN, RP
    MAMON, H
    COLLIER, RJ
    ROBERTS, TM
    SCIENCE, 1994, 266 (5182) : 126 - 129
  • [48] Development of selective B-RAF kinase inhibitors
    Jones, John H.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [49] Raf-1 Kinase Inhibitory Protein Expression in Thyroid Carcinomas
    Kim, Hyun-Soo
    Kim, Gou Young
    Lim, Sung-Jig
    Kim, Youn Wha
    ENDOCRINE PATHOLOGY, 2010, 21 (04) : 253 - 257
  • [50] Raf-1 Kinase Inhibitory Protein Expression in Thyroid Carcinomas
    Hyun-Soo Kim
    Gou Young Kim
    Sung-Jig Lim
    Youn Wha Kim
    Endocrine Pathology, 2010, 21 : 253 - 257